| Literature DB >> 26437664 |
Antonio García-Hermoso1, Vicente Martínez-Vizcaíno2,3, Mairena Sánchez-López4,5, Jose I Recio-Rodriguez6, Manuel A Gómez-Marcos7, Luis García-Ortiz8.
Abstract
BACKGROUND: Public health strategies for cardiovascular prevention highlight the importance of physical activity, but do not consider the additional potentially harmful effects of sedentary behavior. This study was conducted between 2010 and 2012 and analyzed between 2013 and 2014. The aim of the study was to analyze the relationship between sedentary behavior and cardiometabolic risk factors in the Spanish adult population and to examine whether this relationship is mediated by moderate-to-vigorous physical activity (MVPA).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26437664 PMCID: PMC4593196 DOI: 10.1186/s12966-015-0244-y
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Baseline demographic and clinical characteristics of subjects
| Total (n = 1122) | Men (n = 427) | Women (n = 695) |
| |
|---|---|---|---|---|
| Age (years) | 55.0 (0.4) | 57.6 (0.5) | 53.4 (0.4) | <0.001 |
| Smoking status. n (%) | ||||
| Yes | 224 (20.0) | 79 (18.6) | 144 (21.4) | <0.001 |
| No or past | 898 (80.0) | 352 (81.4) | 546 (78.6) | |
| Alcohol status. n (%) | ||||
| Yes | 710 (63.2) | 314 (73.5) | 396 (57.0) | <0.001 |
| No or past | 412 (36.8) | 113 (26.5) | 299 (43.0) | |
| Weight (kg) | 72.4 (0.4) | 81.0 (0.5) | 67.0 (0.4) | <0.001 |
| Height (cm) | 163.3 (0.2) | 170.8 (0.3) | 158.6 (0.2) | <0.001 |
| Body mass index (kg/m2) | 26.8 (24.1-29.8) | 27.4 (25.6-30.1) | 26.0 (22.9-29.5) | 0.001 |
| Waist circumference (cm) | 92.0 (85.0-100.0) | 97.0 (92.0-104.0) | 88.0 (81.0-96.0) | <0.001 |
| Triglycerides (mg/dL) | 95.0 (71.0-131.0) | 107.0 (80.5-152.2) | 87.0 (66.0-121.0) | <0.001 |
| HDL-cholesterol (mg/dL) | 58.0 (48.0-68.0) | 50.0 (43.0-59.0) | 62.0 (53.0-72.0) | <0.001 |
| TG/HDL-C (mg/dL) | 1.6 (1.1-2.5) | 2.0 (1.4-3.4) | 1.4 (1.0-2.2) | <0.001 |
| HOMA-IR | 1.4 (0.8-2.2) | 1.7 (0.9-2.5) | 1.3 (0.8-2.1) | 0.005 |
| Lipid-lowering drugs, n (%) | 187 (16.7) | 98 (23.0) | 89 (12.8) | <0.001 |
| Office systolic blood pressure (mmHg) | 125 (0.6) | 130 (0.7) | 121 (0.5) | <0.001 |
| Office diastolic blood pressure (mmHg) | 77 (0.3) | 78 (0.4) | 75.8 (0.3) | <0.001 |
| Mean arterial blood pressure (mmHg) | 91 (0.4) | 96 (0.4) | 88 (0.4) | <0.001 |
| Antihypertensive drugs, n (%) | 322 (28.7) | 261 (61.1) | 156 (22.4) | <0.001 |
| Time accelerometer worn, min/day | 931.2 (9.5) | 941.6 (11.2) | 924.8 (8.0) | 0.239 |
| Used valid days, n | 5.5 (0.1) | 5.4 (0.1) | 5.6 (0.1) | 0.994 |
| MVPA, min/day | 46.5 (1.1) | 53.8 (1.5) | 42.0 (0.9) | <0.001 |
| Meet recommendations for MVPAa. n (%) | 582 (51.9) | 224 (52.4) | 355 (51.1) | 0.003 |
| Sedentary time, min/day | 580.3 (7.8) | 601.7 (9.0) | 567.2 (6.3) | 0.003 |
HDL high-density lipoprotein, TG triglycerides, MVPA moderate-to-vigorous physical activity
Values are means (standard deviations (SE)) for normally distributed continuous data and medians (interquartile range (IQR)) for asymmetrically distributed continuous data and number and proportions (%) for categorical data; a150 min/week of MVPA [14]
Mean differences in cardiometabolic risk parameters by sedentary time categories controlling for potential confounders, by sex
| Crude data | Model 1 | Model 2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (L) | Medium (M) | High (H) |
| Low (L) | Medium (M) | High (H) |
| Low (L) | Medium (M) | High (H) |
| |
| BMI | ||||||||||||
| Men | 28.0 ± 0.4 | 28.1 ± 0.3 | 28.2 ± 0.4 | 0.997 | 27.6 ± 0.6 | 28.1 ± 0.3 | 28.6 ± 0.5 | 0.968 | 27.9 ± 0.6 | 28.1 ± 0.3 | 28.1 ± 0.5 | 0.955 |
| Women | 26.4 ± 0.4 | 27.0 ± 0.3 | 27.2 ± 0.4 | 0.595 | 25.9 ± 0.5 | 26.9 ± 0.3 | 27.9 ± 0.5 | 0.215 | 26.5 ± 0.6 | 26.9 ± 0.3 | 27.3 ± 0.5 | 0.283 |
| WC | ||||||||||||
| Men | 98.1 ± 1.2 | 98.6 ± 0.8 | 98.9 ± 1.1 | 0.891 | 96.5 ± 1.5 | 98.6 ± 0.8 | 100.4 ± 1.4 | 0.985 | 97.2 ± 1.5 | 98.7 ± 0.8 | 99.5 ± 1.4 | 0.972 |
| Women | 89.3 ± 1.0 | 89.8 ± 0.7 | 90.3 ± 1.0 | 0.776 | 86.5 ± 1.2 | 89.5 ± 0.7 | 90.4 ± 1.2 | 0.496 | 87.8 ± 1.3 | 89.6 ± 0.7 | 92.1 ± 1.2 | 0.741 |
| TG | ||||||||||||
| Men | 131.3 ± 9.1 | 124.3 ± 6.0 | 124.3 ± 8.8 | 0.664 | 126.3 ± 11.9 | 124.7 ± 6.1 | 128.1 ± 10.8 | 0.755 | 127.2 ± 12.3 | 124.8 ± 6.2 | 127.8 ± 11.3 | 0.826 |
| Women | 92.4 ± 4.6 | 102.9 ± 3.1 | 103.3 ± 4.4 | 0.009 | 80.9 ± 5.6 | 102.5 ± 2.9 | 115.2 ± 5.1a | 0.016 | 85.7 ± 5.8 | 102.6 ± 2.9 | 110.2 ± 5.3a | 0.024 |
| HDL-C | ||||||||||||
| Men | 51.4 ± 1.4 | 51.5 ± 0.9 | 52.9 ± 1.3 | 0.571 | 53.3 ± 1.8 | 51.1 ± 0.9 | 51.9 ± 1.6 | 0.801 | 52.5 ± 1.8 | 51.0 ± 0.9 | 52.8 ± 1.7 | 0.832 |
| Women | 64.7 ± 1.3 | 62.5 ± 0.8 | 63.4 ± 1.2 | 0.688 | 66.5 ± 1.6 | 64.3 ± 0.8 | 65.3 ± 1.5 | 0.505 | 66.2 ± 1.7 | 62.2 ± 0.8 | 62.7 ± 1.6 | 0.433 |
| TG/HDL-C ratio | ||||||||||||
| Men | 2.6 ± 0.2 | 2.7 ± 0.2 | 2.9 ± 0.2 | 0.020 | 2.0 ± 0.3 | 2.6 ± 0.2b | 2.8 ± 0.3a | 0.022 | 2.7 ± 0.4 | 2.6 ± 0.1 | 1.7 ± 0.3 | 0.800 |
| Women | 1.6 ± 0.1 | 1.8 ± 0.1 | 2.2 ± 0.1 | 0.015 | 1.3 ± 0.1 | 1.8 ± 0.1b | 2.1 ± 0.1a | 0.035 | 1.4 ± 0.1 | 1.8 ± 0.1 | 1.9 ± 0.1 | 0.433 |
| HOMA-IR | ||||||||||||
| Men | 1.5 ± 0.1 | 1.8 ± 0.1 | 2.0 ± 0.2 | <0.001 | 1.2 ± 0.2 | 2.0 ± 0.1 | 2.1 ± 0.2a | 0.008 | 1.3 ± 0.2 | 1.6 ± 0.1 | 1.8 ± 0.2 | 0.168 |
| Women | 1.3 ± 0.1 | 1.7 ± 0.1 | 1.9 ± 0.1 | 0.005 | 1.0 ± 0.2 | 1.7 ± 0.1 | 2.2 ± 0.1a | 0.017 | 1.5 ± 0.2 | 1.7 ± 0.1 | 2.0 ± 0.2 | 0.318 |
| MAP | ||||||||||||
| Men | 98.0 ± 1.3 | 97.0 ± 0.8 | 96.0 ± 1.2 | 0.636 | 98.9 ± 1.7 | 96.8 ± 0.9 | 95.4 ± 1.5 | 0.720 | 98.7 ± 1.7 | 96.8 ± 0.9 | 95.7 ± 1.6 | 0.725 |
| Women | 89.6 ± 1.0 | 91.3 ± 0.7 | 91.0 ± 1.0 | 0.102 | 89.4 ± 1.3 | 90.8 ± 0.9 | 92.1 ± 1.2 | 0.076 | 89.9 ± 1.4 | 90.9 ± 0.7 | 91.5 ± 1.2 | 0.083 |
Values are means ± SE. HDL high-density lipoprotein, MAP mean arterial pressure, TG triglycerides, WC waist circumference
Model 1: adjusted for age, smoking habit, drinking habit, and time accelerometer worn; TG, HDL-C and TG-HDL-C ratio was additionally adjusted for the use of lipid-lowering drugs (yes/no); MAP was additionally adjusted for the use of antihypertensive drugs (yes/no). Model 2: model 1 covariates + moderate-to-vigorous physical activity (mean min/day). a L < H; b M < H
Mean differences in cardiometabolic risk parameters by MVPA categories controlling for potential confounders, by sex
| Crude data | Model 1 | Model 2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (L) | Medium (M) | High (H) |
| Low (L) | Medium (M) | High (H) |
| Low (L) | Medium (M) | High (H) |
| |
| BMI | ||||||||||||
| Men | 29.5 ± 0.4 | 27.6 ± 0.3 | 27.6 ± 0.4 | <0.001 | 29.6 ± 0.4 | 27.6 ± 0.3b | 27.5 ± 0.4a | <0.001 | 29.2 ± 0.7 | 27.5 ± 0.3b | 28.0 ± 0.8a | 0.001 |
| Women | 28.3 ± 0.4 | 26.7 ± 0.3 | 26.1 ± 0.4 | 0.008 | 28.3 ± 0.4 | 26.7 ± 0.3 | 26.0 ± 0.4a | 0.005 | 27.1 ± 0.6 | 27.0 ± 0.7 | 26.6 ± 0.3a | 0.005 |
| WC | ||||||||||||
| Men | 101.8 ± 1.1 | 99.2 ± 0.8 | 97.8 ± 1.1 | 0.002 | 102.1 ± 1.1 | 97.2 ± 0.8 | 93.6 ± 1.1a | 0.002 | 101.3 ± 1.8 | 97.1 ± 0.8 | 98.5 ± 2.1a | 0.002 |
| Women | 93.2 ± 1.0 | 89.5 ± 0.7 | 87.0 ± 0.9 | 0.001 | 92.7 ± 1.0 | 89.7 ± 0.7 | 87.1 ± 0.9a | <0.001 | 90.8 ± 1.5 | 89.8 ± 1.7 | 89.4 ± 0.7a | <0.001 |
| TG | ||||||||||||
| Men | 131.9 ± 8.6 | 122.6 ± 6.2 | 126.3 ± 8.7 | 0.660 | 129.8 ± 8.8 | 123.3 ± 6.3 | 125.1 ± 8.8 | 0.164 | 124.1 ± 14.5 | 122.7 ± 6.4 | 134.0 ± 16.5 | 0.181 |
| Women | 114.1 ± 4.5 | 99.7 ± 3.1 | 89.3 ± 4.4 | 0.002 | 113.2 ± 4.3 | 100.2 ± 3.0 | 89.2 ± 4.2a | <0.001 | 106.7 ± 6.7 | 99.3 ± 3.0 | 97.1 ± 7.5a | 0.001 |
| HDL-C | ||||||||||||
| Men | 49.9 ± 1.3 | 51.5 ± 0.9 | 54.4 ± 1.3 | 0.056 | 50.5 ± 1.3 | 51.6 ± 0.9 | 53.7 ± 1.3 | 0.553 | 50.6 ± 2.1 | 51.6 ± 0.9 | 53.6 ± 2.5 | 0.554 |
| Women | 59.7 ± 1.2 | 63.4 ± 0.9 | 63.4 ± 1.2 | 0.002 | 59.8 ± 1.3 | 63.4 ± 0.8 | 66.3 ± 1.2a | 0.005 | 60.3 ± 1.9 | 63.5 ± 0.9 | 65.6 ± 2.2a | 0.005 |
| TG/HDL-C ratio | ||||||||||||
| Men | 2.9 ± 0.2 | 2.6 ± 0.1 | 2.6 ± 0.2 | 0.443 | 2.9 ± 0.2 | 2.6 ± 0.2 | 2.7 ± 0.2 | 0.336 | 2.7 ± 0.4 | 2.6 ± 0.2 | 2.9 ± 0.5 | 0.345 |
| Women | 2.1 ± 0.1 | 1.7 ± 0.1 | 1.5 ± 0.1 | <0.001 | 2.1 ± 0.1 | 1.7 ± 0.1 | 1.5 ± 0.1a | <0.001 | 2.0 ± 0.2 | 1.7 ± 0.1 | 1.5 ± 0.2a | <0.001 |
| HOMA-IR | ||||||||||||
| Men | 2.3 ± 0.2 | 1.8 ± 0.1 | 1.5 ± 0.2 | <0.001 | 2.4 ± 0.1 | 1.7 ± 0.1 | 1.4 ± 0.2a | 0.002 | 2.3 ± 0.2 | 1.7 ± 0.1 | 1.5 ± 0.3a | 0.002 |
| Women | 2.1 ± 0.1 | 1.6 ± 0.1 | 1.3 ± 0.1 | 0.001 | 2.1 ± 0.1 | 1.6 ± 0.1 | 1.3 ± 0.1a | <0.001 | 2.0 ± 0.2 | 1.7 ± 0.1 | 1.6 ± 0.2a | <0.001 |
| MAP | ||||||||||||
| Men | 96.8 ± 1.2 | 96.7 ± 0.9 | 97.6 ± 1.2 | 0.831 | 96.9 ± 1.3 | 96.8 ± 0.9 | 97.5 ± 1.3 | 0.785 | 98.7 ± 2.0 | 96.9 ± 0.9 | 95.3 ± 2.3 | 0.791 |
| Women | 91.0 ± 1.0 | 90.8 ± 0.7 | 90.6 ± 1.0 | 0.835 | 90.8 ± 1.0 | 90.9 ± 0.7 | 90.5 ± 0.9 | 0.666 | 90.1 ± 1.5 | 90.4 ± 0.1 | 95.0 ± 1.7 | 0.676 |
Values are means ± SE. HDL high-density lipoprotein, MAP mean arterial pressure, TG triglycerides, WC waist circumference
Model 1: adjusted for age, smoking habit, drinking habit, and time accelerometer worn; TG, HDL-C and TG-HDL-C ratio was additionally adjusted for the use of lipid-lowering drugs (yes/no); MAP was additionally adjusted for the use of antihypertensive drugs (yes/no). Model 2: model 1 covariates + moderate-to-vigorous physical activity (mean min/day). a L > H; b L > M
Fig. 1MVPA mediation model of the relationship between sedentary time and HOMA-IR, adjusting for potential confounders, by sex. Data in roman type refer to men. Data in italics refer to women. a p ≤ 0.05; b p ≤ 0.001